BOLT

Bolt Biotherapeutics, Inc.

1.16 USD
-0.02 (-1.69%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Bolt Biotherapeutics, Inc. stock is up 8.41% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 February’s closed higher than January.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.